130 related articles for article (PubMed ID: 12879476)
1. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis.
Pakos EE; Kyzas PA; Ioannidis JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6208-14. PubMed ID: 15448009
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study.
Pösl M; Amling M; Grahl K; Hentz M; Ritzel H; Werner M; Winkler K; Delling G
Gen Diagn Pathol; 1997 Jun; 142(5-6):317-25. PubMed ID: 9228255
[TBL] [Abstract][Full Text] [Related]
4. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
5. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
6. Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype.
Radig K; Häckel C; Herting J; Oda Y; Mittler U; Neumann W; Roessner A
Gen Diagn Pathol; 1997 Feb; 142(3-4):139-45. PubMed ID: 9065577
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis.
Wang Z; He ML; Zhao JM; Qing HH; Wu Y
Asian Pac J Cancer Prev; 2013; 14(5):2753-8. PubMed ID: 23803027
[TBL] [Abstract][Full Text] [Related]
8. Association between P-glycoprotein expression and response to chemotherapy in patients with osteosarcoma: a systematic and meta-analysis.
Zhao ZG; Ding F; Liu M; Ma DZ; Zheng CK; Kan WS
J Cancer Res Ther; 2014 Nov; 10 Suppl():C206-9. PubMed ID: 25450283
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Mauri D; Pavlidis N; Ioannidis JP
J Natl Cancer Inst; 2005 Feb; 97(3):188-94. PubMed ID: 15687361
[TBL] [Abstract][Full Text] [Related]
10. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.
Baldini N; Scotlandi K; Barbanti-Bròdano G; Manara MC; Maurici D; Bacci G; Bertoni F; Picci P; Sottili S; Campanacci M
N Engl J Med; 1995 Nov; 333(21):1380-5. PubMed ID: 7477118
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
[TBL] [Abstract][Full Text] [Related]
12. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
14. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
[TBL] [Abstract][Full Text] [Related]
16. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
[TBL] [Abstract][Full Text] [Related]
17. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
Bacci G; Longhi A; Cesari M; Versari M; Bertoni F
Cancer; 2006 Jun; 106(12):2701-6. PubMed ID: 16691623
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome.
Hicks MJ; Roth JR; Kozinetz CA; Wang LL
J Clin Oncol; 2007 Feb; 25(4):370-5. PubMed ID: 17264332
[TBL] [Abstract][Full Text] [Related]
19. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
20. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.
Nathan SS; Gorlick R; Bukata S; Chou A; Morris CD; Boland PJ; Huvos AG; Meyers PA; Healey JH
Cancer; 2006 Oct; 107(7):1607-16. PubMed ID: 16933325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
